Receptos (RCPT) Getting Somewhat Favorable News Coverage, Study Shows

Press coverage about Receptos (NASDAQ:RCPT) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Receptos earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.5682604520403 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/12/receptos-rcpt-getting-somewhat-favorable-news-coverage-study-shows.html.

Receptos Company Profile

Receptos, Inc (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn’s Disease (CD).

Insider Buying and Selling by Quarter for Receptos (NASDAQ:RCPT)

Receive News & Ratings for Receptos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Receptos and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit